ArticleRMD open2026
Real-world damage accrual in Sjögren's disease: a 5-year multicentre GIRRCS cohort analysis.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary Sjögren's disease (SD) is a systemic autoimmune disorder causing glandular dysfunction, sicca symptoms and extraglandular manifestations, which impair quality of life. Data on early irreversible damage and its predictors remain limited.
methodsWe conducted a multicentre retrospective cohort study of 429 adult patients with SD from the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale network with ≥1 year of follow-up. Baseline assessments included disease activity (European League Against Rheumatism (EULAR), Sjögren's Syndrome Disease Activity Index (ESSDAI)), patient-reported symptoms (EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)), C reactive protein (CRP), Schirmer's test (ST) and autoantibody status. Irreversible damage was evaluated using the Sjögren's Syndrome Damage Index (SSDI) across ocular, oral and systemic domains. Predictors of damage accrual were analysed using Cox proportional hazards models and Kaplan-Meier curves. Exploratory Least Absolute Shrinkage and Selection Operator (LASSO) and principal component analysis (PCA) analyses assessed domain-specific contributions and relationships between subjective and objective measures.
resultsAt baseline, 48% of patients had SSDI≥1: ocular 25.4%, systemic 22.5% and oral 14.3%. After 5 years, 65% had cumulative damage: ocular 34.2%, oral 21.7% and systemic 40.8%. Higher baseline ESSDAI predicted damage across all domains. Elevated ESSPRI was associated with oral damage, while abnormal ST strongly predicted ocular damage. Anti-Ro/La antibodies, elevated CRP and recurrent oral infections were linked to higher domain-specific damage. LASSO analyses showed glandular, peripheral nervous system and pulmonary ESSDAI domains independently contributed to systemic damage. PCA confirmed that patient-reported symptoms and systemic activity represent complementary, independent dimensions.
conclusionIrreversible damage in SD occurs early, often present at diagnosis and affects multiple organ domains. Early identification of high-risk patients, based on clinical, serological and patient-reported measures, may enable timely interventions to prevent further damage, guide treatment and improve long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.